Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Investors Begin To Differentiate Solazyme's Unique Technology

As seen in the chart below, it appears that renewable oil producer Solazyme (SZYM) has begun to stand apart from its supposed industry peer group over the last few months. Although often lumped together with struggling advanced biofuel and biochemical producers such as Amyris (AMRS), Gevo (GEVO), and KiOR (KIOR), Solazyme has begun to distinguish itself as investors begin to comprehend the vast distinctions between these companies. Apart from its superior balance sheet, operational traction, and magnetic appeal to landing industry-leading partners, Solazyme's comparative advantage is beginning to be understood in the company's biotechnology toolkit.

SZYM data by YCharts

Over the past decade, Solazyme has refined its technology to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details